China’BGI Genomics exports
its thalassemia detection kits in Azerbaijan
Azerbaijan Thalassemia Center will be one of Chinese BGI’s pioneer overseas thalassemia projects in a country with a high prevalence rate of this disease.
On 6th September 2022, the Azerbaijan Thalassemia Center and BGI Genomics held a virtual signing ceremony to seal a collaboration agreement aiming to improve thalassemia screening in Azerbaijan through genetic technology. Headquartered in Shenzhen China, BGI Genomics is providing thalassemia genetic testing services based on next-generation sequencing (NGS) technology since 2013. In early 2021, in occasion of the “Prevention and Control of Global Haemoglobinopathies” announcement, BGI Poverty Prevention and Control Panel clearly stated they seek to export China’s advanced technologies for thalassemia to ‘Belt and Road Initiative’ countries, to jointly achieve comprehensive thalassemia control in the global community. In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, obtained the medical device registration certificate from the National Drug Administration for its alpha and beta thalassemia gene detection kit (combining probe anchored polymerisation sequencing method).
The collaboration agreement was signed by Dr. Valeh Hüseynov, the Executive Director of National Hematology and Transfusiology Center, Dr. Agha Rza Aghayev, the supervisor of Azerbaijan’s medical genetics department, and Mr. Jeremy Cao, the Vice President of BGI IntDx. The two organizations have entered a strategic partnership and will work together for a thalassemia study research project in the country.
Attendees from Azerbaijan Thalassemia Center: Dr. Khuraman Jafarova, Chief Doctor of Thalassemia Center, vice director of National Hematology and Transfusiology Center; Dr. Afsana Mammadova, Head of Clinical Diagnostics Laboratory, Supervisor of Biochemistry; Dr. Adam Najafli, Head of Cytogenetics Laboratory, Medical Genetics Department; Dr. Agha Rza Aghayev, Head of Medical Genetics Department, Supervisor of Molecular Genetics. ©BGI Genomics
“Azerbaijan is one of the countries with the highest prevalence rate of thalassemia,” said Zhiyu Peng, BGI Genomics vice president. “Our thalassemia gene detection testing combines cutting-edge high throughput sequencing platform and advantages of low cost and comprehensive detection. It helps scientific research partnership in methodology comparison, enhances new technology collaboration in the clinical testing and explore the screening of thalassemia in Azerbaijan. BGI also has a world hemoglobinopathy foundation focusing on fighting thalassemia worldwide, our goal is making the world a better place without this disease. BGI therefore proposes this agreement to reaffirm that we stand together with Azerbaijan’s thalassemia center and its people.”
18/09/2022
China’BGI Genomics exports its thalassemia detection kits in Azerbaijan
China’BGI Genomics exports
its thalassemia detection kits in Azerbaijan
Azerbaijan Thalassemia Center will be one of Chinese BGI’s pioneer overseas thalassemia projects in a country with a high prevalence rate of this disease.
On 6th September 2022, the Azerbaijan Thalassemia Center and BGI Genomics held a virtual signing ceremony to seal a collaboration agreement aiming to improve thalassemia screening in Azerbaijan through genetic technology. Headquartered in Shenzhen China, BGI Genomics is providing thalassemia genetic testing services based on next-generation sequencing (NGS) technology since 2013. In early 2021, in occasion of the “Prevention and Control of Global Haemoglobinopathies” announcement, BGI Poverty Prevention and Control Panel clearly stated they seek to export China’s advanced technologies for thalassemia to ‘Belt and Road Initiative’ countries, to jointly achieve comprehensive thalassemia control in the global community. In April 2022, BGI’s wholly-owned subsidiary, Huada Biotechnology (Wuhan) Co., Ltd, obtained the medical device registration certificate from the National Drug Administration for its alpha and beta thalassemia gene detection kit (combining probe anchored polymerisation sequencing method).
The collaboration agreement was signed by Dr. Valeh Hüseynov, the Executive Director of National Hematology and Transfusiology Center, Dr. Agha Rza Aghayev, the supervisor of Azerbaijan’s medical genetics department, and Mr. Jeremy Cao, the Vice President of BGI IntDx. The two organizations have entered a strategic partnership and will work together for a thalassemia study research project in the country.
Attendees from Azerbaijan Thalassemia Center: Dr. Khuraman Jafarova, Chief Doctor of Thalassemia Center, vice director of National Hematology and Transfusiology Center; Dr. Afsana Mammadova, Head of Clinical Diagnostics Laboratory, Supervisor of Biochemistry; Dr. Adam Najafli, Head of Cytogenetics Laboratory, Medical Genetics Department; Dr. Agha Rza Aghayev, Head of Medical Genetics Department, Supervisor of Molecular Genetics. ©BGI Genomics
“Azerbaijan is one of the countries with the highest prevalence rate of thalassemia,” said Zhiyu Peng, BGI Genomics vice president. “Our thalassemia gene detection testing combines cutting-edge high throughput sequencing platform and advantages of low cost and comprehensive detection. It helps scientific research partnership in methodology comparison, enhances new technology collaboration in the clinical testing and explore the screening of thalassemia in Azerbaijan. BGI also has a world hemoglobinopathy foundation focusing on fighting thalassemia worldwide, our goal is making the world a better place without this disease. BGI therefore proposes this agreement to reaffirm that we stand together with Azerbaijan’s thalassemia center and its people.”
18/09/2022
COMMENTS ARE OFF THIS POST